

One Wales

Gail Woodland, Senior Appraisal Pharmacist, AWTTTC



AWTTTC

All Wales Therapeutics
& Toxicology Centre

Background

- Developed in 2016 to provide All Wales interim commissioning decisions for medicines not currently suitable for Health Technology Appraisal (HTA)
- Unmet need identified within the service
- Includes off-label/unlicensed medicines
- Identified mainly through collation of IPFR data for potential cohorts
- ‘Interim Pathways Commissioning Group (IPCG)’ draws members from across all health boards/IPFR panels
- Recommendations from IPCG are submitted to the Chief Executives group who make the final decision
- Decisions are reviewed at least annually
- Requirement by service to collect patient outcome data

Identification of medicines

- Majority (78%) identified through collation of IPFR data and identifying cohorts
- Remainder flagged by health board pharmacists, clinicians and IPFR panels



One Wales work programme

Medicine	Indication	Interim Pathways Commissioning Group (IPCG) Meeting Date	Chief Executive Endorsement Date	Decision
Axitinib (Inlyta [®])	Treatment of advanced renal cell carcinoma after failure of prior treatment with pazopanib	27/05/2016	03/08/2016	Supported
Docetaxel	In combination with androgen deprivation therapy for the treatment of hormone-naïve metastatic prostate cancer	27/05/2016	03/08/2016	Supported
Bevacizumab (Avastin [®])	At a dose of 7.5 mg/kg in combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer	27/05/2016	03/08/2016	Not supported
Adalimumab (Humira [®])	Treatment of paediatric patients with severe refractory non-infectious uveitis	22/08/2016	11/10/2016	Supported
Adalimumab (Humira [®])	Treatment of adult patients with severe refractory non-infectious uveitis	22/08/2016	11/10/2016	Supported
Arsenic trioxide (TRISENOX [®])	Acute promyelocytic leukaemia - 1st line therapy in patients unsuitable for anthracycline-based therapy	26/09/2016	24/10/2016	Supported
Denosumab (Prolia [®])	Treatment of osteoporosis in men at increased risk of fractures	26/09/2016 and 28/11/2016	06/03/2017	Supported
Rituximab (Mabthera [®]) + bendamustine	Treatment of indolent lymphomas, first line and relapsed. To include follicular lymphoma, Waldenström's and marginal zone lymphoma	27/03/2017	-	-
Rituximab (Mabthera [®]) + bendamustine	Treatment of mantle cell lymphoma, first line and relapsed	27/03/2017	-	-

Medicines not considered suitable for One Wales process

- NICE/AWMSG positive recommendation published
- Health technology appraisal (HTA) in progress with NICE or AWMSG
- Negative NICE/AWMSG advice published
- HTA directed by Welsh Government
- Uncertainty over patient cohorts
- Suitable licensed alternative medicines available
- Clinical experts did not identify unmet clinical need
- Clinical network issue
- Medicine made available by Welsh Government

<https://www.awttc.org/pams/one-wales-interim-commissioning-process>

 [Home](#) > [PAMS](#) > [One Wales Interim Commissioning Process](#)

One Wales Interim Commissioning Process

PAMS co-ordinates the new One Wales Interim Commissioning Process ([policy available here](#)), implemented to promote equity of access to those medicines not routinely available in NHS Wales in circumstances where an unmet clinical need has been identified for a patient cohort.

Current One Wales Interim Commissioning Process decisions and work programme can be [accessed here](#).

- ✓ [Background](#)
- ✓ [Will unlicensed or off-label medicines be considered?](#)
- ✓ [Who will make the decisions?](#)
- ✓ [What are the clinicians' responsibilities?](#)
- ✓ [What are the health boards' responsibilities?](#)
- ✓ [How long will One Wales Interim Commissioning Decisions apply?](#)



PAMS
Patient Access to
Medicines Service

[About us](#)

[Individual Patient Funding Request \(IPFR\)](#)

[One Wales Interim Commissioning Process](#)

[Health Technology Assessment \(HTA\)](#)

[Resources](#)

[Contact us](#)



WAPSU
Welsh Analytical Prescribing
Support Unit



WeMeReC
Welsh Medicines Resource
Centre





AWTTC
All Wales Therapeutics
& Toxicology Centre

www.awttc.org

All Wales Therapeutics and Toxicology Centre
Academic Building
University Hospital Llandough
Penlan Road
Penarth
Vale of Glamorgan
CF64 2XX



PAMS
Patient Access to
Medicines Service



WeMeReC
Welsh Medicines
Resource Centre



WAPSU
Welsh Analytical
Prescribing Support Unit



WNPU
Welsh National
Poisons Unit



Yellowcard
Centre
Wales